Side-by-side · Research reference
CardiogenvsKPV
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED5/46 cited
BAnimal-StrongAUTO-DRAFTED13/39 cited
Cardiogen
Bioregulator · Cardiac
CardiacTissue target
Gene regulationMechanism
AnimalEvidence level
SQ · Variable protocols
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
01Mechanism of Action
Parameter
Cardiogen
KPV
Primary target
Cardiovascular cell gene expressionKhavinson 2022
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Pathway
Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
Downstream effect
Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Feedback intact?
Presumed — peptide bioregulators act via gene regulation, not receptor agonism
No melanocortin receptor binding
Origin
Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Antibody development
—
—
02Dosage Protocols
Parameter
Cardiogen
KPV
Standard dose
Variable — typically 10–20 mg per course
No standardised human protocol; animal-derived dosing.
200–500 mcg / day SQ or oralDalle-Pang 2024
Frequency
Intermittent courses — 10–20 days, repeated periodically
Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.
Daily or 2–3× per week
Evidence basis
Animal models / mechanistic studies
No Phase 1+ human trials in PubMed.
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Route
Subcutaneous injection
—
Duration
10–20 day courses, repeated 2–4× per year
Russian geriatric protocols; unclear extrapolation to general populations.
4–8 weeks per cycle
Lower / starter dose
—
100 mcg / day
Reconstitution
—
Bacteriostatic water (SQ form)
Timing
—
No specific time; often taken with / before meals (oral)
Half-life
—
Hours (estimated; rapid tissue uptake)
04Side Effects & Safety
Parameter
Cardiogen
KPV
Injection site reactions
Mild erythema, induration (presumed)
—
Systemic adverse events
No documented serious AEs in available literature
Very limited safety data; no rigorous pharmacovigilance.
—
Immunogenicity
Unknown — no antibody development studies published
—
Long-term safety
Unknown — no extended human trials indexed in PubMed
Limited human data
Injection site reaction
—
Mild irritation
GI symptoms
—
Rare nausea (oral form)
Pregnancy / OB
—
Avoid — insufficient data
Absolute Contraindications
Cardiogen
- ·Active malignancy (theoretical peptide growth factor concern)
- ·Hypersensitivity to peptide components
KPV
- ·Pregnancy / breastfeeding
Relative Contraindications
Cardiogen
- ·Acute cardiac events (no safety data in acute MI, unstable angina)
- ·Pregnancy / lactation (no reproductive toxicity data)
KPV
- ·Active autoimmune disease (theoretical)
05Administration Protocol
Parameter
Cardiogen
KPV
1. Reconstitution
Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.
Add 1 mL bacteriostatic water to vial per labelling.
2. Injection site
Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
3. Timing
Variable — often evening injection. No established circadian preference.
Morning preferred; oral form taken with / before meals.
4. Storage
Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
27–30G insulin syringe, 45° angle for subcutaneous administration.
29–31G insulin syringe (SQ form).
06Stack Synergy
Cardiogen
+ Thymalin
ModerateKhavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.
- Cardiogen
- 10–20 mg SQ · 10–20 day course
- Thymalin
- 10–30 mg IM · concurrent or sequential courses
- Frequency
- 2–4 courses per year
- Primary benefit
- Multi-system aging mitigation, cardiovascular and immune homeostasis
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions